-
Product Insights
NewNet Present Value Model: MacroGenics Inc’s MGC-018
Empower your strategies with our Net Present Value Model: MacroGenics Inc's MGC-018 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Melanoma Drug Details: Vobramitamab duocarmazine (MGC-018) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Pancreatic Cancer Drug Details: Vobramitamab duocarmazine (MGC-018)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Hepatocellular Carcinoma Drug Details: Vobramitamab duocarmazine (MGC-018)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Renal Cell Carcinoma Drug Details: Vobramitamab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Solid Tumor Drug Details: Vobramitamab duocarmazine (MGC-018)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Ovarian Cancer Drug Details: Vobramitamab duocarmazine (MGC-018)...
-
Product Insights
Cerebral Palsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Cerebral Palsy - Drugs In Development, 2023’, provides an overview of the Cerebral Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...